CDRH Review Of Expanded Imaging Agent Indications Urged By NEMA
This article was originally published in The Gray Sheet
Executive Summary
CDRH should serve as the lead reviewer for premarket applications of already-approved contrast agents indicated for use with diagnostic imaging devices, according to Philips Medical Systems VP-Quality & Regulatory Affairs Terry Sweeney
You may also be interested in...
Philips Intera MR Subject Of Warning Letter For Unapproved Perfusion Claim
FDA's recent warning letter to Philips Medical regarding promotion of magnetic resonance (MR) scanners for cardiac perfusion studies is symptomatic of the industry's struggle to find a regulatory pathway to approval for the indication
Philips Intera MR Subject Of Warning Letter For Unapproved Perfusion Claim
FDA's recent warning letter to Philips Medical regarding promotion of magnetic resonance (MR) scanners for cardiac perfusion studies is symptomatic of the industry's struggle to find a regulatory pathway to approval for the indication
Combo Products Meeting Will Address Cross-Labeling, Dual Applications
Diagnostic ultrasound, magnetic resonance imaging and contrast agent companies will hold a series of meetings with FDA to address issues related to their respective device and drug premarket approvals